Shares of Ligand Pharmaceuticals LGND were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share rose 128.17% over the past year to $1.62, which beat the estimate of $0.99.
Revenue of $69,990,000 higher by 159.19% from the same period last year, which beat the estimate of $54,090,000.
Looking Ahead
The upcoming fiscal year's EPS expected to be $6.15.
The upcoming fiscal year's revenue expected to be $291,000,000.
Conference Call Details
Date: Feb 03, 2021
Time: 08:30 AM
ET Webcast URL: https://investor.ligand.com/ir-calendar
Price Action
52-week high: $198.79
Company's 52-week low was at $57.24
Price action over last quarter: Up 113.61%
Company Description
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
